Session Type: Poster Session (Monday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Drug survival is used as a tool for treatment effectiveness and safety especially in real-world data. The objective of the study was to evaluate long term survival of subcutaneous TNF inhibitors (TNFi) in spondyloarthritis (SA) patients and to compared drug survival between the different lines.
Methods: Multicentric, retrospective, longitudinal and observational study included all patients with SA under TNFi since 2004, with a record in RIC France. The first part of the study analysed the survival of the fourth anti-TNF : etanercept (ETN), adalimumab (ADA), golimumab (GOL) and certolizumab (CTZ) since their first prescription. The second part of the study included the patients from January 2013 to March 2018, as CTZ has been available in January 2013. Drug survival has been analysed at 6 months, 1, 2, 3 et 5 years for the 1st, 2nd et 3rd course with Kaplan-Meier test compared with log-rank test.
Results: On the total population (n=1170), ADA and ETN has a comparable mean drug survival (MDS) of 42 and 46 months respectively. CTZ has a MDS of 16 weeks and GOL of 60 weeks.
When we analysed the records of the 425 patients treated since January 2013 (836 TNFi treatment) the characteristics were at TNFi initiation : a mean-age of 43.3 years, 45.6% female, mean SA duration of 8.6 years (+/- 12) and the mean BASDAI was 5.43. 824 TNFi have been analysed and 439 were on course
418 first course TNFi with a drug survival at one year at 70 % for adalimumab (ADA), at 58 % for etanercept (ETA), at 85 % for certolizumab (CTZ) and at 83% pour le golimumab (GOL).
In second course of TNFi (n=230), drug survival was at one year of 58 % for ADA, at 62 % ETA, at 57 % for CTZ. and 66 % for GOL.
In third course or more (n=176) drug survival was at one year of 67% for ADA, 76% for ETA, 51% for CTZ and 86% for GOL.
Data for predicting factors of survival are on analysed.
Conclusion: In this retrospective study of real world, golimumab has the best drug survival, in the long-term evaluation as well as the 5 years evaluation and also whatever the line of treatment. Predicting factors of survival might explain this result.
To cite this abstract in AMA style:Baudens G, Coquerelle P, Guyot M, Loiseau-Pères S, Marguerie L, Maury F, Eric V, Letarouilly J, Salmon J, Flipo R, Gervais E. Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/real-life-12-year-retention-rate-of-subcutaneous-anti-tnf-in-spondyloarthritis-results-from-a-multicenter-cohort-of-1170-patients/. Accessed October 27, 2021.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-life-12-year-retention-rate-of-subcutaneous-anti-tnf-in-spondyloarthritis-results-from-a-multicenter-cohort-of-1170-patients/